Proveris Scientific names Ramesh Chand as Associate Director of rapidly growing GMP contract test business, Proveris Laboratories

Proveris Scientific Corporation, a leading provider of instrumentation and services to advance the science of aerosol and spray products, today announced Ramesh Chand has been named Associate Director of Proveris Scientific’s rapidly growing GMP contract test business, Proveris Laboratories.

Ramesh Chand is a scientific expert with more than 16 years of professional experience within the Orally Inhaled and Nasal Drug Product (OINDP) development community, including analytical, formulation development, process development, device selection and characterization, scale-up/technical transfer and preclinical aerosol development on both innovator and generic drug products. His work also encompasses nebulization and nose-to-brain nasal delivery of biologics. As Associate Director of Proveris Laboratories, he will oversee the day-to-day laboratory operations, ensuring quality and regulatory standards are upheld and will assist Proveris Research in introducing innovative technologies to advance inhalation science and development. His diverse expertise will shape strategic direction and will allow Proveris to expand their menu of services.

Ramesh earned his Master of Science in chemical engineering, from Missouri University of Science and Technology, which included thesis work focused on ‘Generation and Characterization of Aerosols.’ Prior to joining Proveris, he worked for Moderna Therapeutics in Cambridge, MA as the Principal Scientist of Drug Product Development (Respiratory), Amneal Pharmaceuticals, Piscataway, NJ as a Senior Research Scientist, Inhalation Product Development, Lovelace Biomedical, Albuquerque, NM as Senior Research Associate and GlaxoSmithKline, Research Triangle Park, NC as an Associate Scientist, Inhaled Product Development. With his regular contributions to research, Ramesh has co-authored more than 15 respiratory articles.

“Ramesh is a significant addition to the Proveris Laboratories team,” commented Dino Farina, CEO, Proveris Scientific. “His experience in OINDP drug development combined with his research will provide our customers access to proven expertise that will help them achieve their goals quickly and at the highest quality. In addition, he will be a key player in helping Proveris Research deliver new and innovative technologies through Proveris Labs for the advancement of inhalation science and drug development”

Ramesh added, “I am excited to join Proveris at a time when the company is rapidly advancing the test services business. Proveris is uniquely positioned in supporting OINDP development programs. I believe the addition of innovative technologies and expanded capabilities will immensely benefit customer’s respiratory drug development.”

About Proveris Scientific
Proveris Scientific Corporation advances the science of respiratory drug delivery products by driving innovative technology development for high performance spray characterization, capture, and analysis, while leveraging its expertise, experience, and core technologies. With customer success as its central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” which include product innovation, technical services, systems, consumables, and educational training. Since its founding in 1995, the company has accelerated the development of top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2015 by TÜV Rheinland of North America, Inc., and has more than 20 patents issued on its technology.